Olaparib

FDA Approved: * December 19, 2014
Pharm Company: * ASTRAZENECA PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Olaparib Overview

Olaparib (AZD-2281, MK-7339 trade name Lynparza) is an FDA-approved targeted therapy for cancer. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.[1] In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA.[2][3][4&...

Read more Olaparib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Olaparib

Recent Olaparib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Olaparib or a similar ingredient: (1 result)

• LYNPARZA Olaparib1 discussion